GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Saniona AB (STU:30S) » Definitions » Valuation Rank

Saniona AB (STU:30S) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Saniona AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Saniona AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Saniona AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Saniona AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Saniona AB (STU:30S) » Definitions » Valuation Rank
Comparable Companies
XSAT:HAMLET B OSTO:MAGLE OSTO:SYNACT OSTO:DMYD B OSTO:FLUO OSTO:IBT B OSTO:IRLAB A OSTO:INIT OSTO:CANTA OSTO:IVACC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SANION:Sweden 0RQJ:UK 30S:Germany
Address
Smedeland 26B, Glostrup, DNK, DK-2600
Website
https://www.saniona.com
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219.